LENZ Therapeutics (LENZ) Total Current Liabilities (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Total Current Liabilities data on file, last reported at $25.8 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $25.8 million, up 201.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.8 million (up 201.16% YoY), and the FY2025 annual result was $21.2 million, up 103.6% from the prior year.
• Total Current Liabilities climbed to $25.8 million in Q1 2026 per LENZ's latest filing, from $21.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $25.8 million in Q1 2026 and troughed at $7.7 million in Q3 2024.
• A 5-year average of $13.9 million and a median of $12.8 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities slumped 54.63% in 2025, then soared 201.16% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $13.0 million in 2022, then surged by 41.95% to $18.5 million in 2023, then plunged by 43.79% to $10.4 million in 2024, then surged by 103.6% to $21.2 million in 2025, then gained by 21.8% to $25.8 million in 2026.
• Business Quant data shows LENZ's Total Current Liabilities at $25.8 million in Q1 2026, $21.2 million in Q4 2025, and $16.3 million in Q3 2025.